<DOC>
	<DOCNO>NCT01323907</DOCNO>
	<brief_summary>The purpose study provide use Omegaven infant life threaten Total Parenteral Nutrition ( TPN ) associate cholestasis medical surgical treatments/therapies either ineffective feasible treatment serious condition . This compassionate use protocol .</brief_summary>
	<brief_title>Compassionate Use Omegaven IV Fat Emulsion</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Diagnosis life threaten PNALD Dependent Parenteral Nutrition caloric need Expected require PN least another 30 day Other cause liver disease exclude GI/Liver service involve patient care standard therapy treatment PNALD must utilize prior initiate omegaven . Under care attend Neonatologist NICU Must least 2 month age Not NICU patient Younger 2 month age Expected weaned parenteral nutrition within 30 day document cause liver disease sign proven severe advanced liver disease Allergy seafood , egg protein and/or previous allergy Omegaven active coagulopathy , impaired lipid metabolism severe hyperlipidemia without pancreatitis , stoke , embolism , hemodynamic collapse shock , recent MI , cholestasis due reason PNALD , active new infection time initiation Omegaven , hemodynamic instability unable tolerate necessary laboratory monitoring must enrol another clinical trial involve investigational agent ( unless approve designated physician ) . Parent legal guardian must willing provide consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Total Parenteral Nutrition-induced Cholestasis</keyword>
	<keyword>Omegaven</keyword>
	<keyword>liver disease</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Fat emulsion</keyword>
</DOC>